Sugi Predict

Sugi Predict / Compounds / SCHEMBL506373

SCHEMBL506373

SCHEMBL506373

COc1ccc(CN)cc1Cl

nearest known ligand 0.66

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ CSNK2A1 P68400 7/20 0.66
▸ MEN1 O00255 2/20 0.56
▸ KMT2A Q03164 2/20 0.56
▸ ALDH1A1 P00352 1/20 0.56
▸ SMN1; SMN2 Q16637 2/20 0.53
▸ TTR P02766 1/20 0.50
▸ HSD17B10 Q99714 1/20 0.49
▸ KDM4E B2RXH2 1/20 0.48
▸ ATM Q13315 1/20 0.48
▸ MRGPRX4 Q96LA9 1/20 0.46
▸ TAAR1 Q96RJ0 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ CA2 P00918 1/20 0.45
▸ GLA P06280 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL856874 0.98 CSNK2A1 (0.67) CSNK2A1MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL28467993 0.87 CSNK2A1 (0.60) CSNK2A1MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL8349185 0.85 KDM4E (0.56) CSNK2A1MEN1KMT2AALDH1A1KDM4E
SCHEMBL714973 0.85 KDM4E (0.70) MEN1KMT2AALDH1A1SMN1; SMN2KDM4E
SCHEMBL16216977 0.85 CSNK2A1 (0.53) CSNK2A1MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL559310 0.84 CSNK2A1 (0.51) CSNK2A1MEN1KMT2AALDH1A1TTR
SCHEMBL29673212 0.84 CSNK2A1 (0.51) CSNK2A1MEN1KMT2AALDH1A1TTR
SCHEMBL4976340 0.83 TTR (0.67) CSNK2A1MEN1KMT2AALDH1A1SMN1; SMN2
Hydrochloric Acid SCHEMBL1467248 0.83 KDM4E (0.68) CSNK2A1MEN1KMT2AALDH1A1SMN1; SMN2
Hydrochloric Acid SCHEMBL8299478 0.82 CSNK2A1 (0.53) CSNK2A1MEN1KMT2AALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 397 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109280049-B Synthetic method of medical compound avanafil 重庆奥舍生物化工有限公司 2021-02-02 — — CN claimed
CN-109280050-B Preparation method of medical compound avanafil 重庆奥舍生物化工有限公司 2021-01-29 — — CN claimed
CN-109280049-A A kind of synthetic method of pharmaceutical compound avanaphil 重庆奥舍生物化工有限公司 2019-01-29 — — CN claimed
CN-109280050-A A kind of preparation method of pharmaceutical compound avanaphil 重庆奥舍生物化工有限公司 2019-01-29 — — CN claimed
CN-109232542-A A method of preparing pharmaceutical compound avanaphil 重庆奥舍生物化工有限公司 2019-01-18 — — CN claimed
US-10059654-B2 Composition containing 3-chloro-4-methoxybenzylamine hydrochloride, and method for producing same AIR WATER INC. (JP) 2018-08-28 — — US claimed
CN-104557877-B A kind of avanaphil intermediate and its preparation method and application 重庆安格龙翔医药科技有限公司 2016-08-17 — — CN claimed
CN-105712893-A 3-chloro-4-methoxy benzyl amine synthetic method 重庆安格龙翔医药科技有限公司 2016-06-29 — — CN claimed
CN-105712891-A Method used for preparing high purity 3-chloro-4-methoxybenzylamine 重庆安格龙翔医药科技有限公司 2016-06-29 — — CN claimed
CN-103483323-B Ai Wanafei SUZHOU UUGENE BIOPHARMA CO., LTD. (CN) 2016-01-20 — — CN claimed
US-6723848-B2 TETRAHYDROBENZOFURAN OR TETRAHYDROBENZOTHIOPHEN OR TETRAHDYROBENZOPYRROLE COMPOUNDS CAN BE AROMATIZED WITH A HYDROGENATION CATALYST IN PRESENCE OF A HYDROGEN ACCEPTOR, DEACYLATION OF AMINO GROUP BY ADDITION OF AN AMINE GROUP MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 2004-04-20 — — US claimed
US-20040053945-A1 Process for the preparation of a pyrazolo[4,3-d]pyrimidine derivative MERCK PATENT GMBH (DE) 2004-03-18 — — US claimed
CN-1481243-A Pharmaceutical formulation contg. thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2) Ĭ��ר���ɷ����޹�˾ 2004-03-10 — — CN claimed
EP-1358189-A1 PROCESS FOR THE PREPARATION OF A PYRAZOLO 4,3-D]PYRIMIDINE DERIVATIVE MERCK PATENT GmbH (DE) 2003-11-05 — — EP claimed
CN-1439012-A 2-zminoalkyl-thieno [2,3-D] pyrimidines MERCK PATENT GMBH (DE) 2003-08-27 — — CN claimed
CN-1422265-A Process for producing benzo-fused heterocycle MERCK PATENT GMBH (DE) 2003-06-04 — — CN claimed
US-20030078422-A1 Method for producing benzo annelated heterocycles MERCK PATENT GMBH (DE) 2003-04-24 — — US claimed
EP-1280792-A1 METHOD FOR PRODUCING BENZO ANNELATED HETEROCYCLES MERCK PATENT GmbH (DE) 2003-02-05 — — EP claimed
WO-2002059126-A1 PROCESS FOR THE PREPARATION OF A PYRAZOLO[4,3-D]PYRIMIDINE DERIVATIVE MERCK PATENT GMBH (DE) 2002-08-01 — — WO claimed
WO-2001077099-A1 METHOD FOR PRODUCING BENZO ANNELATED HETEROCYCLES MERCK PATENT GMBH (DE) 2001-10-18 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10059654-B2 Composition containing 3-chloro-4-methoxybenzylamine hydrochloride, and method for producing same CMBL, HAO2, CPNE4 CSNK2A1 449/4885MEN1 1142/4885KMT2A 144/4885
US-20030078422-A1 Method for producing benzo annelated heterocycles NAT1, AFF1, SAT1 CSNK2A1 1340/4885MEN1 903/4885KMT2A 824/4885
US-20040053945-A1 Process for the preparation of a pyrazolo[4,3-d]pyrimidine derivative HPD, DDC, KMO CSNK2A1 695/4885MEN1 900/4885KMT2A 925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback